Partner Therapeutics, Inc.

Jim Cramer discusses Merus N.V. (MRUS) under his lightning rounds spotlight, noting its speculative nature despite FDA approval for cancer therapy Bizengri. Cramer cautions against market complacency and overly optimistic expectations for Federal Reserve rate cuts, highlighting the potential for disappointment. MRUS ranks 3rd on the list, with AI stocks seen as more promising for higher returns.

DelveInsight's report on the Gene and Cell Therapies Targeting CNS Disorders market forecasts growth to 2034, highlighting key companies and therapies, including Bayer AG's Phase Ib clinical trial success for Parkinson's disease and uniQure's positive trends in Huntington's disease trials. The market, valued at approximately USD 1 billion in 2021, is expected to surge due to increasing disease prevalence and pipeline product launches.